Introduction
The epidermal growth factor receptor (EGFR) is expressed or amplified in a broad range of non-small cell lung cancers (NSCLC). It is, therefore, regarded as a major driving force in the development of lung cancer in concert with other less frequent molecular disturbances, such as amplification and mutation of the catalytic subunit of PI3-kinase (PIK3CA), k-Ras, c-MET, or the EML4-Alk translocation [1] . However, the efficacy of EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib is largely limited to tumors whose cells harbor activating mutations in the EGFR tyrosine kinase domain, a rather small fraction amounting to 5 -20% of the EGFR-positive lung tumors in Caucasian patients. Moreover, virtually all of the NSCLC tumors that initially respond to EGFR tyrosine kinase inhibitors eventually develop drug resistance resulting in disease progression and patient death. The mechanisms that underlie acquired resistance to EGFR tyrosine kinase inhibitors are highly diverse. They may include (but may not be limited to) secondary mutations of the EGFR, amplification of c-Met and Her2, mutations of PIK3CA, activation of the Axl-kinase, activation of VEGF or IGF-1 pathways, epithelial-to-mesenchymal transition, or transformation into small cell lung cancer [2] . As part of the CESAR network on systems pharmacology, we applied a global strategy to decipher the complex resistance mechanisms in EGFR-mutated NSCLC cell lines with acquired resistance to EGFR tyrosine kinase inhibition [3] .
Material and methods
The NSCLC cell line HCC4006 was obtained from ATCC (Manassas, VA, USA). The sub-lines with acquired resistance to gefitinib or erlotinib were established as described previously [4] and are part of the Resistant Cancer Cell Line (RCCL) collection. The cell lines were designated as HC-C4006 r GEFI 1 (gefitinib-resistant) and HC-C4006 r ERLO 1 (erlotinib-resistant). All cell lines were cultivated in DMEM/HAM's F12 medium supplemented with 10% fetal bovine serum at 37 °C in a humidified 5% carbon dioxide atmosphere. Affinity purification of the EGFR and characterization of the EGFR 1/2014 (92-94) interactome was carried out using biotinylated cetuximab conjugated to magnetic streptavidin beads and subsequent high resolution mass spectrometry as described previously [5] . Expression of the microRNA-family 200 (miR-141, miR-200a, b and c, miR-429) was characterized by qPCR (Taqman assay using RNU6B as internal reference; Ambion) after isolation of total RNA from HCC4006 cell lines.
Results
Affinity purification of the EGFR and the associated protein complex identified 780 EGFR-associated proteins in HCC4006 cells and 755 EGFR-associated proteins in HCC4006 r ERLO 1 cells. 535 proteins were shared among the EGFR complexes in both cell lines. 18 proteins were found to be > 5-fold enriched (Table 1) , 81 proteins were found to be > 2-fold enriched, and 36 proteins were found exclusively present in the EGFR-associated protein complex in HC-C4006 r ERLO 1 cells compared to HCC4006 cells. The Gene Ontology analysis of these 117 enriched or exclusively present proteins by web-based g:profiler (www.biit.cs.ee/ gprofiler/index.cgi; [6] ) revealed a significant enrichment of proteins assigned to cellular compartments of macromolecular complex (p = 6.8 × 10 -8 ) or intracellular non-membrane bounded organelle (p = 5.3 × 10 -12 ), the biological process of cellular component organisation or biogenesis (p = 5.2 × 10 -7 ), and the molecular function of actin binding (p = 3.4 × 10 -9 ). 18 proteins assigned to actin binding included those labeled bold in Table  1 plus filamin-B, drebrin, synaptopodin, gelsolin, nexilin, myosin subunits 9, 10, and 14, myosin phosphatase rho-interacting protein, and actin-related protein 2/3 complex subunit 2. All of these proteins significantly shared the cellular compartment of the actin cytoskeleton (p = 4.8 × 10 -18 ) and the biological process of actin cytoskeleton organization (p = 6.8 × 10 -15 ). As actin cytoskeleton (re)organization is part of the epithelial-tomesenchymal transition (EMT) process, we sought to find additional mechanistic evidence for this process in HCC4006 r ERLO 1 cells. Previous results from chemoresistant colon carcinoma models suggested that the microRNA 200 family is involved in EMT [7] . Therefore, expression of this microRNA family was investigated in HCC4006 r ERLO 1 cells compared to HCC4006 cells. Although transcribed from a single promoter, expression of the mature microRNAs differed signif- 
Conclusions
Metastatic NSCLC remains associated with an extremely poor prognosis resulting in a median survival of less than 1 year. Resistance acquisition remains a major obstacle for the successful treatment of this disease. We detected an elevated recruitment of EMT-related proteins to the EGFR and a reduced expression of miR-200 family members in erlotinib-and gefitinib-resistant NSCLC cells. These findings strongly suggest that EMT is involved in NSCLC cell resistance acquisition to EGFR inhibitors. Our on-going investigations will further decipher the role of EMT and other mechanisms in acquired EGFR tyrosine kinase resistance at a systems pharmacology level in NSCLC. The resulting enhanced global understanding of the processes that result in acquired NSCLC cell resistance to EGFR tyrosine kinase inhibitors (and subsequently other drugs) will be a key prerequisite for the rational development of improved therapeutic strategies for this devastating disease.
